XML 67 R55.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 7 - Stockholders' Equity (Deficit) (Details Textual)
3 Months Ended 9 Months Ended 12 Months Ended
Jul. 27, 2016
$ / shares
shares
Jun. 27, 2016
$ / shares
shares
Apr. 15, 2016
$ / shares
shares
Feb. 12, 2016
USD ($)
$ / shares
shares
Apr. 01, 2012
shares
Sep. 30, 2016
$ / shares
shares
Mar. 31, 2016
USD ($)
Sep. 30, 2016
USD ($)
$ / shares
shares
Dec. 31, 2015
USD ($)
$ / shares
shares
Dec. 31, 2014
USD ($)
$ / shares
shares
Jun. 26, 2016
$ / shares
shares
Oct. 02, 2015
$ / shares
shares
Oct. 01, 2015
shares
Dec. 31, 2013
shares
Mar. 15, 2006
shares
Common Stock, Shares Authorized 100,000,000 100,000,000       100,000,000   100,000,000 20,000,000 20,000,000 100,000,000,000 20,000,000 10,000,000    
Common Stock, Par or Stated Value Per Share | $ / shares $ 0.0001 $ 0.0001   $ 0.0001   $ 0.0001   $ 0.0001 $ 0.0001 $ 0.001 $ 0.000001 $ 0.001      
Preferred Stock, Shares Authorized 20,000,000 20,000,000       20,000,000   20,000,000 20,000,000   5,000,000,000        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number           2,592,229   2,592,229 1,707,744 1,217,744       977,744  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross               1,974,445 490,000 240,000          
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares               $ 1.25 $ 1.25 $ 1          
Allocated Share-based Compensation Expense | $               $ 450,566              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares               133,229              
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                 $ 1            
Series B Preferred Stock [Member]                              
Preferred Stock, Shares Authorized           18,000,000   18,000,000 18,000,000            
Predecessor Warrants [Member] | Series B Preferred Stock [Member]                              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       295,945                      
Private Placement [Member] | Series B Preferred Stock [Member]                              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       423,291                      
Class of Warrant or Right, Expiration Period       5 years                      
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares       $ 1.25                      
Private Placement [Member] | Placement Agent Warrants [Member]                              
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares     $ 1.25                        
Private Placement [Member] | Placement Agent Warrants [Member] | Series B Preferred Stock [Member]                              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights     127,346                        
Protagenic Therapeutics Inc [Member]                              
Business Combination, Stock Warrant Conversion Ratio       1                      
Debt Instrument, Face Amount | $       $ 665,000                      
Debt Instrument, Increase, Accrued Interest | $       $ 35,000                      
Class of Warrant or Right, Expiration Period       5 years                      
Protagenic Therapeutics Inc [Member] | Predecessor Warrants [Member]                              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       295,945                      
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares       $ 1.25                      
Protagenic Therapeutics Inc [Member] | Placement Agent Warrants [Member]                              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       127,346                      
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares       $ 1.25                      
Protagenic Therapeutics Inc [Member] | Private Placement [Member]                              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       3,403,367                      
Each Member of Board of Directors [Member]                              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross     40,000                        
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares     $ 1.25                        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Additional     5,000                        
Director [Member]                              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross     175,000                        
Employees and Consultants [Member]                              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross     1,008,299                        
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares     $ 1.25                        
Former Executives [Member]                              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross           17,785                  
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares               $ 1.25              
Employee Stock Option [Member]                              
Allocated Share-based Compensation Expense | $                 $ 190,751 $ 85,168          
Employee Stock Option [Member] | Each Member of Board of Directors [Member]                              
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period     2 years                        
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period     10 years                        
Employee Stock Option [Member] | Employees and Consultants [Member]                              
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period     4 years                        
Employee Stock Option [Member] | Former Executives [Member]                              
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period               3 years              
Employee Stock Option [Member] | Minimum [Member] | Employees and Consultants [Member]                              
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period     10 years                        
Employee Stock Option [Member] | Maximum [Member] | Employees and Consultants [Member]                              
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period     1 year                        
The 2006 Plan [Member]                              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number           2,592,229   2,592,229 292,256 782,256          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross                 490,000 240,000          
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares                 $ 1.25 $ 1          
The 2006 Plan [Member] | Chief Financial Officer [Member]                              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross       100,000                      
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares       $ 1.25                      
The 2006 Plan [Member] | Employee Stock Option [Member]                              
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized         2,000,000 2,000,000   2,000,000             140,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period               5 years              
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period               10 years 10 years            
The 2006 Plan [Member] | Employee Stock Option [Member] | Chief Financial Officer [Member]                              
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period       3 years                      
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period       10 years                      
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting, Number of Monthly Installments       35                      
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting, Monthly Installment, Shares       0.18                      
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting, Final Monthly Installment, Shares       2,778                      
Allocated Share-based Compensation Expense | $             $ 5,192 $ 10,383              
The 2006 Plan [Member] | Employee Stock Option [Member] | Minimum [Member]                              
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period         1 year     1 year 180 days            
The 2006 Plan [Member] | Employee Stock Option [Member] | Maximum [Member]                              
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period         5 years       5 years            
Stock Conversion from Series B Preferred Stock to Common Stock [Member]                              
Convertible Preferred Stock, Shares Issued upon Conversion 1 1                          
Reverse Stock Split [Member]                              
Stockholders' Equity Note, Stock Split, Conversion Ratio   15,463.7183                          
Reverse Stock Split [Member] | Series B Preferred Stock [Member]                              
Stockholders' Equity Note, Stock Split, Conversion Ratio 15,463.7183     15,463.7183